Jcog0405
WebPatients received two or three cycles of preoperative chemotherapy of irinotecan plus cisplatin in JCOG0001, or S-1 plus cisplatin in JCOG0405, followed by D3 gastrectomy. … Web2 set 2024 · For patients with bulky N2 and PAN metastases, the 3-year and 5-year OS rates were 7.4% and 0.0%, respectively, which were lower than those of the JCOG0405 study (20.0% and 20.0%). Conclusion: The results of our study suggest that D2 lymphadenectomy alone is suitable for GC patients with only bulky N2 metastasis after …
Jcog0405
Did you know?
Web12 set 2024 · The RR was 64.7% in the JCOG0405, and the efficacy of DCS therapy was expected to be superior to that of CS therapy in the JCOG0405. The sample size was calculated to be 50 cases, under the hypothesis that the expected RR and threshold RR were 80% and 65%, respectively, with use of one-sided testing at the 10% significance … WebThe 3-year and 5-year survival rates in the JCOG1002 study were 62.7% and 54.9%, respectively, which were similar to those in the JCOG0405 study. At present, the standard therapy for these patients in Japan is still that stated in the JCOG0405 protocol. All three studies (JCOG0001, JCOG0405 and JCOG1002) combined PCT with D2 gastrectomy …
Web5 mar 2024 · JCOG conducted another phase II study to evaluate the efficacy and safety of the preoperative chemotherapy with S-1 + cisplatin, which was the same regimens as … http://www.jcog.jp/document/0405.pdf
WebJCOG0405ver1.5 3/68 14） 適切な腎機能が保たれている。 Web過去の臨床試験. HOME ＞ 臨床試験報告 ＞ 過去の臨床試験. 【JCOG9501】. 大動脈周囲リンパ節郭清の臨床的意義に関する研究. 【JCOG9502】. 食道浸潤胃がんの外科治療に関する比較臨床試験. 【JCOG0001】. 高度リンパ節転移を伴う進行胃がんに対する術 …
Web3 set 2013 · JCOG0405 trial because barium X-rays and endoscopic. examinations were not performed after neoadjuvant. chemotherapy. Validity of response criteria in gastric cancer 515. 123.
Web3 set 2013 · Patient population. We included all eligible patients from two clinical trials (JCOG0210 and JCOG0405) that were conducted by the JCOG. These phase II trials aimed to evaluate the efficacy and safety of neoadjuvant S-1 plus cisplatin in gastric cancer patients [7, 8].The eligibility criteria of the JCOG0210 trial included linitis plastica … pekin couch disposalWeb16 giu 2016 · Background: Gastric cancer with extensive lymph node metastasis is commonly considered unresectable, with a poor prognosis. We previously reported the results of the use of cisplatin and S-1 as preoperative chemotherapy for gastric cancer with extensive lymph node metastasis; docetaxel, cisplatin, and S-1 (DCS) have now been … mech owa mail.milWeb(JCOG0001 and JCOG0405) to evaluate the safety and efficacy of preoperative chemotherapy followed by gas-trectomy with D2 plus PAN dissection for gastric cancer … mech of the week pantherWebThe pathological RR defined as residual tumor corresponding to less than one-third the size of the original tumor was 34.6% in 52 eligible patients, which was slightly higher than in JCOG0405 (28.6%). Among all eligible patients, 5-year overall survival was 54.9% (95% confidence interval 40.3–67.3%) at the date cut-off of May 2024. mech one mechanicalWeb1 feb 2011 · 90 Background: GC with ELM (bulky N2 metastasis and / or para-aortic lymph node metastases [PAN]) is commonly regarded unresectable, while in JCOG combined … pekin correctional facilityWebBackground: Locally advanced gastric cancer with extensive regional and/or para-aortic lymph node (PAN) metastases is typically unresectable and associated with poor outcomes. This study investigated the safety and efficacy of S-1 plus cisplatin followed by extended surgery with PAN dissection for gastric cancer with extensive lymph node metastasis. mech other word forWeb21 mar 2024 · An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Hiroshi Katayama. Akira Tsuburaya. Mitsuru Sasako. mech origin